(Q37679938)

21 August 2017

1 reference

title

Colorectal cancer in review: the role of the EGFR pathway (English)

1 reference

21 August 2017

1 reference

1 reference

Muhammad W Saif

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

19

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

357-369

1 reference

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

The ERBB3 receptor in cancer and cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Regulation of cyclooxygenase-2 pathway by HER2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Harnessing preclinical mouse models to inform human clinical cancer trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Chemoprevention of breast cancer: a model for change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Monoclonal antibodies as therapeutic agents for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Monoclonal antibodies as therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Epidermal growth factor receptor biology (IMC-C225).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

ErbB-targeted therapeutic approaches in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003593962

10.1517/13543781003593962

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference